-
Atomoxetine Capsules USP 80mg, Exempt Medicinal Product (Glenmark Pharmaceuticals Inc. livery)
Feb 14, 2025, 16:37 -
PRAC meeting highlights 10-13 February 2025
Feb 14, 2025, 00:00 -
Summary of Field Safety Notices October 2024
Feb 12, 2025, 15:14 -
Summary of Field Safety Notices January 2025
Feb 12, 2025, 14:39 -
Summary of Field Safety Notices September 2024
Feb 12, 2025, 09:36 -
Summary of Field Safety Notices May 2024
Feb 11, 2025, 14:26 -
Summary of Field Safety Notices April 2024
Feb 11, 2025, 12:24 -
Summary of Field Safety Notices November 2024
Feb 7, 2025, 16:27 -
Atomoxetine Capsules USP 25mg and Atomoxetine Capsules USP 40mg, Exempt Medicinal Products (Glenmark Pharmaceuticals Inc. livery)
Feb 7, 2025, 16:26 -
Summary of Field Safety Notices December 2024
Feb 7, 2025, 16:26 -
PRAC meeting highlights 13-16 January 2025
Jan 17, 2025, 12:44 -
Veoza (fezolinetant) - Risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment
Jan 13, 2025, 00:00 -
Alofisel (darvadstrocel) – Withdrawal from EU market
Dec 19, 2024, 09:31 -
Medtronic MiniMed 600 and 700 series Insulin Pumps – Priority 2 – Warning
Dec 16, 2024, 00:00 -
PRAC meeting highlights 25-28 November 2024
Nov 29, 2024, 12:41 -
Drug Safety Newsletter – Edition 117 – 29 November 2024
Nov 29, 2024, 12:04 -
Update – McGrath MAC Video Laryngoscope – Priority 1 – For Immediate Action
Nov 8, 2024, 00:00 -
Epilim Syrup 200mg 5ml Oral Solution – Change in syrup colour
Nov 7, 2024, 15:34 -
Codinex codeine phosphate 15 mg/5 ml oral solution – Reclassification to prescription-only medicine
Nov 1, 2024, 12:45 -
PRAC meeting highlights 28-31 October 2024
Oct 28, 2024, 00:00
